Best Nanotechnology Stocks To Follow Now - April 27th

OSI Systems, NVE, and Clene are the three Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Error: Response status code does not indicate success: 429 (Too Many Requests). These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

Shares of OSI Systems stock traded down $0.63 during trading on Friday, hitting $201.68. 102,437 shares of the stock traded hands, compared to its average volume of 185,105. The stock has a market cap of $3.39 billion, a price-to-earnings ratio of 25.96, a PEG ratio of 1.81 and a beta of 1.19. The company has a quick ratio of 1.25, a current ratio of 1.88 and a debt-to-equity ratio of 0.56. OSI Systems has a 52 week low of $129.18 and a 52 week high of $220.00. The firm's fifty day moving average is $192.59 and its 200-day moving average is $177.59.

Read Our Latest Research Report on OSIS

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NVE stock traded up $0.63 during mid-day trading on Friday, hitting $58.47. The company's stock had a trading volume of 13,675 shares, compared to its average volume of 22,443. The stock has a market cap of $282.82 million, a price-to-earnings ratio of 18.86 and a beta of 1.05. NVE has a 12 month low of $51.50 and a 12 month high of $89.98. The business has a 50 day moving average price of $63.50 and a 200-day moving average price of $72.78.

Read Our Latest Research Report on NVEC

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

CLNN stock traded down $0.17 during midday trading on Friday, hitting $3.00. The company had a trading volume of 94,234 shares, compared to its average volume of 78,139. The stock has a market cap of $25.79 million, a price-to-earnings ratio of -0.57 and a beta of 0.46. Clene has a 52 week low of $2.57 and a 52 week high of $9.20. The stock's 50 day moving average price is $3.67 and its 200 day moving average price is $4.51.

Read Our Latest Research Report on CLNN

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.